Benefit-Risk Assessment
TABLE OF CONTENTS
Volume 82, Issue 2 (August 2007)
Editorial |
News & Views |
Perspectives |
State of the Art |
Research |
Discovery & Development |
Regulation & Use
Contents
Contents
In this issue
Clin Pharmacol Ther 82: 107; doi:10.1038/sj.clpt.6100287
See also: Point/Counterpoint by Hughes et al. See also: Point/Counterpoint by TempleSee also: State of the Art by Almenoff et al. See also: Development by Sistare & DeGeorgeSee also: Public Policy by MeyerEditorial
Benefit and Risk Assessment in Drug Development and Utilization: A Role for Clinical Pharmacology
P Honig
Clin Pharmacol Ther 82: 109-112; doi:10.1038/sj.clpt.6100277
News & Views
Highlights
News and Views
Clin Pharmacol Ther 82: 114-115; doi:10.1038/sj.clpt.6100279
ASCPT News
ASCPT News
Clin Pharmacol Ther 82: 116-117; doi:10.1038/sj.clpt.6100280
Macroscopy
Role of the Centers for Education and Research on Therapeutics (CERTs) in Pharmacovigilance and Proper Use of Therapeutics
H H Tilson, L K Madre and R M Califf
Clin Pharmacol Ther 82: 118-121; doi:10.1038/sj.clpt.6100251
Perspectives
Point/Counterpoint
Current Assessment of Risk–Benefit by Regulators: Is It Time to Introduce Decision Analyses?
D A Hughes, A M Bayoumi and M Pirmohamed
Clin Pharmacol Ther 82: 123-127; doi:10.1038/sj.clpt.6100240
Quantitative Decision Analysis: A Work in Progress
R Temple
Clin Pharmacol Ther 82: 127-130; doi:10.1038/sj.clpt.6100239
Commentaries
The Pharmaceutical Industry at Risk: How Excessive Government Regulation Stifles Innovation
R A Epstein
Clin Pharmacol Ther 82: 131-132; doi:10.1038/sj.clpt.6100257
Safety Monitoring of Drugs Granted Exclusivity Under the Best Pharmaceuticals for Children Act: What the FDA has Learned
L L Mathis and S Iyasu
Clin Pharmacol Ther 82: 133-134; doi:10.1038/sj.clpt.6100285
Pharmacology Education in Undergraduate and Graduate Medical Education in the United States
C Candler, M Ihnat and G Huang
Clin Pharmacol Ther 82: 134-137; doi:10.1038/sj.clpt.6100266
Pharmacometrics and the Transition to Model-Based Development
T H Grasela, C W Dement, O G Kolterman, M S Fineman, D M Grasela, P Honig, E J Antal, T D Bjornsson and E Loh
Clin Pharmacol Ther 82: 137-142; doi:10.1038/sj.clpt.6100270
State of the Art
State of the Art
Developments in Post-marketing Comparative Effectiveness Research
S Schneeweiss
Clin Pharmacol Ther 82: 143-156; advance online publication, June 6, 2007; doi:10.1038/sj.clpt.6100249
Novel Statistical Tools for Monitoring the Safety of Marketed Drugs
J S Almenoff, E N Pattishall, T G Gibbs, W DuMouchel, S J W Evans and N Yuen
Clin Pharmacol Ther 82: 157-166; advance online publication, May 30, 2007; doi:10.1038/sj.clpt.6100258
Research
Articles
Patient-reported Adverse Events Under Asthma Therapy: A Community Pharmacy-based Survey
L Laforest, E Van Ganse, G Devouassoux, L M Osman, G Bauguil and G Chamba
Clin Pharmacol Ther 82: 167-172; advance online publication, May 9, 2007; doi:10.1038/sj.clpt.6100224
An Evaluation of Computer-Aided Disproportionality Analysis for Post-Marketing Signal Detection
H P Lehman, J Chen, A L Gould, R Kassekert, P R Beninger, R Carney, M Goldberg, M A Goss, K Kidos, R G Sharrar, K Shields, A Sweet, B E Wiholm and P K Honig
Clin Pharmacol Ther 82: 173-180; advance online publication, May 16, 2007; doi:10.1038/sj.clpt.6100233
Inhibition of PKC 
by Ruboxistaurin Does Not Enhance the Acute Blood Pressure Response to Nitroglycerin
C Benson, M Seger and J Voelker
Clin Pharmacol Ther 82: 181-186; advance online publication, April 18, 2007; doi:10.1038/sj.clpt.6100210
Polymorphisms of ACE2 Gene are Associated With Essential Hypertension and Antihypertensive Effects of Captopril in Women
X Fan, Y Wang, K Sun, W Zhang, X Yang, S Wang, Y Zhen, J Wang, W Li, Y Han, T Liu, X Wang, J Chen, H Wu and R Hui and the study group for "Pharmacogenomic based Antihypertensive Drugs Selection, effects and side effects, in Rural Area Chinese”"
Clin Pharmacol Ther 82: 187-196; advance online publication, May 2, 2007; doi:10.1038/sj.clpt.6100214
Amodiaquine Metabolism is Impaired by Common Polymorphisms in CYP2C8: Implications for Malaria Treatment in Africa
S Parikh, J-B Ouedraogo, J A Goldstein, P J Rosenthal and D L Kroetz
Clin Pharmacol Ther 82: 197-203; advance online publication, March 14, 2007; doi:10.1038/sj.clpt.6100122
Discovery & Development
Translation Medicine
The Challenge of Treating Biofilm-associated Bacterial Infections
J L del Pozo and R Patel
Clin Pharmacol Ther 82: 204-209; advance online publication, May 30, 2007; doi:10.1038/sj.clpt.6100247
Development
Preclinical Predictors of Clinical Safety: Opportunities for Improvement
F D Sistare and J J DeGeorge
Clin Pharmacol Ther 82: 210-214; advance online publication, May 16, 2007; doi:10.1038/sj.clpt.6100243
Regulation & Use
Practice
Interethnic Differences in Drug Response: The Contribution of Genetic Variability in 
Adrenergic Receptor and Cytochrome P4502C9
M Muszkat
Clin Pharmacol Ther 82: 215-218; advance online publication, February 28, 2007; doi:10.1038/sj.clpt.6100142
Ethics
Balancing Justice and Autonomy in Clinical Research With Healthy Volunteers
N E Kass, R Myers, E J Fuchs, K A Carson and C Flexner
Clin Pharmacol Ther 82: 219-227; advance online publication, April 4, 2007; doi:10.1038/sj.clpt.6100192
